Artiva Biotherapeutics (ARTV) Insider Trading & Ownership $1.90 -0.10 (-4.75%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Artiva Biotherapeutics (NASDAQ:ARTV) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage21.40%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$30.00 MNumber OfInsiders Selling(Last 12 Months)0 Get ARTV Insider Trade Alerts Want to know when executives and insiders are buying or selling Artiva Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ARTV Insider Buying and Selling by Quarter Artiva Biotherapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/22/2024Global Strategic Fund I VenbioMajor ShareholderBuy416,666$12.00$4,999,992.00 7/22/2024Yong-Jun HuhDirectorBuy2,083,332$12.00$24,999,984.00 (Data available from 1/1/2013 forward) ARTV Insider Trading Activity - Frequently Asked Questions Who is on Artiva Biotherapeutics's Insider Roster? The list of insiders at Artiva Biotherapeutics includes Global Strategic Fund I Venbio, and Yong-Jun Huh. Learn more on insiders at ARTV. What percentage of Artiva Biotherapeutics stock is owned by insiders? 21.40% of Artiva Biotherapeutics stock is owned by insiders. Learn more on ARTV's insider holdings. Which Artiva Biotherapeutics insiders have been buying company stock? The following insiders have purchased ARTV shares in the last 24 months: Global Strategic Fund I Venbio ($4,999,992.00), and Yong-Jun Huh ($24,999,984.00). How much insider buying is happening at Artiva Biotherapeutics? Insiders have purchased a total of 2,499,998 ARTV shares in the last 24 months for a total of $29,999,976.00 bought. Artiva Biotherapeutics Key ExecutivesDr. Fred Aslan M.D. (Age 49)President, CEO & Director Compensation: $917.3kDr. Peter Flynn Ph.D. (Age 50)Co-Founder & Strategic Advisor Compensation: $499.37kMs. Jennifer Kinsbruner Bush Esq. (Age 49)J.D., Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer Compensation: $630.31kMr. Christopher P. Horan (Age 57)Chief Technical Operations Officer Compensation: $612.23kMs. Neha Krishnamohan (Age 37)CFO & Executive VP of Corporate Development Dr. Thorsten Graef M.D. (Age 48)Ph.D., Chief Medical Officer Dr. Heather Raymon Ph.D. (Age 60)Senior Vice President of Research & Early Development Mr. Eugene HelselSenior Vice President of Regulatory AffairsDr. K. C Lim Pharm.D.Senior Vice President of Clinical Operations More Insider Trading Tools from MarketBeat Related Companies OCGN Insider Trades ACTU Insider Trades NVCT Insider Trades ANNX Insider Trades CRGX Insider Trades VYGR Insider Trades YMAB Insider Trades CRDF Insider Trades PRME Insider Trades INMB Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Sprouts Stock: Insider Sales, But Strong Bullish Signals5 Hot Small-Cap Insiders Bought at the Peak of Tariff FearsThe Top-Ranked Insider Buys From April by Market CapMcDonald’s Insiders Sell Shares! Investors Should Do the Opposite This page (NASDAQ:ARTV) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARTV Stock Free ARTV Stock Alerts